Facio presents at the 6th annual Orphan Drugs and Rare Diseases Europe Conference
May 5, 2017
Facio Therapies will present its mission to improve the lives of people with FSHD, and showcase the latest results from its FSHD drug discovery program at the 6th annual Orphan Drugs and Rare Diseases Europe Conference in Berlin, Germany, on May 15th, 2017.
The 6th annual Orphan Drugs and Rare Diseases Europe Conference, is organized by SMI and connects the different stakeholders in the rare disease industry including patient advocates, regulators, pharma, investors and academia. Facio’s Managing Director, David Dasberg, will discuss Facio’s origin, the translation of science into early stage drug discovery, as well as community alignment. Facio’s Case Study: “Breaking Through to an FSHD Therapy” will be held at the Crowne Plaza Berlin – Potsdamer Platz, Berlin, Germany on May 15th, 2017 at 16:30 (CEST).